Trials / Completed
CompletedNCT06460324
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
Assessment of COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab in the United States: A Multicenter Medical Record Review Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 38 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This was a non-interventional, retrospective, observational cohort study involving the abstraction and review of pertinent data from medical records by participating physicians, who completed a customized electronic case report form hosted on the secure electronic data capture system.
Conditions
Timeline
- Start date
- 2022-05-20
- Primary completion
- 2023-07-03
- Completion
- 2023-07-03
- First posted
- 2024-06-14
- Last updated
- 2024-06-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT06460324. Inclusion in this directory is not an endorsement.